Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Precision Biosciences (DTIL) EBIT Margin (2018 - 2025)

Historic EBIT Margin for Precision Biosciences (DTIL) over the last 8 years, with Q3 2025 value amounting to 158976.92%.

  • Precision Biosciences' EBIT Margin fell 1552833500.0% to 158976.92% in Q3 2025 from the same period last year, while for Sep 2025 it was 12822.64%, marking a year-over-year decrease of 128010600.0%. This contributed to the annual value of 38.08% for FY2024, which is 516700.0% up from last year.
  • Per Precision Biosciences' latest filing, its EBIT Margin stood at 158976.92% for Q3 2025, which was down 1552833500.0% from 121538.89% recorded in Q2 2025.
  • Precision Biosciences' EBIT Margin's 5-year high stood at 48.39% during Q2 2024, with a 5-year trough of 158976.92% in Q3 2025.
  • Its 5-year average for EBIT Margin is 19333.07%, with a median of 199.32% in 2022.
  • In the last 5 years, Precision Biosciences' EBIT Margin surged by 30748500bps in 2021 and then plummeted by -1552833500bps in 2025.
  • Over the past 5 years, Precision Biosciences' EBIT Margin (Quarter) stood at 484.68% in 2021, then skyrocketed by 76bps to 114.26% in 2022, then tumbled by -85bps to 211.57% in 2023, then crashed by -1741bps to 3894.36% in 2024, then plummeted by -3982bps to 158976.92% in 2025.
  • Its EBIT Margin stands at 158976.92% for Q3 2025, versus 121538.89% for Q2 2025 and 76248.28% for Q1 2025.